BioMarin Pharmaceutical(US:BMRN) Prnewswire·2025-08-04 20:02Financial Performance - Total Revenues for Q2 2025 were $825 million, representing a 16% increase year-over-year, driven by a 20% growth in VOXZOGO revenue from new patients [5][12][13] - GAAP Net Income increased by $134 million to $241 million, a 125% increase compared to Q2 2024, primarily due to higher gross profit and lower SG&A expenses [5][13][14] - Non-GAAP Income rose by $93 million to $282 million, reflecting a 49% growth year-over-year [5][13][14] Earnings Per Share - GAAP Diluted EPS for Q2 2025 was $1.23, a 124% increase year-over-year [5][13][14] - Non-GAAP Diluted EPS was $1.44, representing a 50% increase compared to the same period in 2024 [5][13][14] Business Development - The acquisition of Inozyme was completed on July 1, 2025, enhancing the company's portfolio with BMN 401 for ENPP1 Deficiency treatment [4][5][13] - BMN 333, a potential treatment for achondroplasia, showed promising early data and is expected to enter pivotal studies in 2026 [3][4][9] Pipeline Progress - VOXZOGO revenue increased by 20% year-over-year, with treatment available for children with achondroplasia in 51 countries [9][10][12] - The company is advancing its CANOPY clinical program for VOXZOGO in additional indications, with pivotal study data expected in 2026 [9][10][12] Operational Efficiency - GAAP Operating Margin expanded to 33.5%, a 16.6 percentage point increase year-over-year, while Non-GAAP Operating Margin reached 39.9%, an 8.7 percentage point increase [13][14] - R&D expenses decreased year-over-year due to focused investment following a strategic portfolio review [13][14] Cash Flow and Guidance - Operating cash flows totaled $185 million in Q2 2025, a 55% increase compared to the same period in 2024 [13][14] - The company raised its full-year 2025 guidance for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS, reflecting continued growth in patient demand [13][17]